Diagnostic Assay For Source of Inflammation

Abstract

A method of diagnosing the source of local, acute inflammation has been developed based on the discovery that white cells have different patterns of gene expression, and therefore protein markers, depending on the origin of the inflammation. These differences can be readily accessed by analysis of the white cells obtained at a site to be analyzed, for example, in the synovial fluid of a knee. The analysis, by comparison with the analysis of white cells present in known conditions, can be used to differentiate between inflammation due to bacterial infection, arthritis or gout, for example. The examples demonstrate differential gene expression in cells present in synovial fluid biopsies from patients with confirmed bacterial infection as compared to patients with aseptic loosening or patients with inflammation due to gout.

1 - 19 . (canceled) 
     
     
         20 . A method of diagnosing the source of local inflammation comprising: determining the expression of one or more genes or proteins encoded thereby in a cell, in a clinical sample obtained from a site of local inflammation, and comparing the expression of the genes or proteins encoded thereby with their expression in known control samples from a comparable site without local inflammation to determine if the site is infected, wherein levels of expression of one or more genes or proteins encoded thereby, indicative of bacterial infection, from the site of local inflammation are altered by at least two fold by bacterial infection, wherein the sample is selected from the group consisting of lymph fluid, cerebrospinal fluid, local fluid, connective, tissue, local tissue, cerebrospinal tissue, and any combination thereof. 
     
     
         21 . The method of  claim 20  wherein the gene expression is detected by examining nucleic acid expression. 
     
     
         22 . The method of  claim 20  wherein the gene expression is detected by examining protein expression. 
     
     
         23 . The method of  claim 20  wherein expression of a gene is determined by assaying for an mRNA transcribed from the gene or a protein translated from an mRNA transcribed from the gene. 
     
     
         24 . The method of  claim 20  wherein the sample comprises neutrophils or other white cells. 
     
     
         25 . The method of  claim 20  wherein the genes are analyzed on a microarray. 
     
     
         26 . The method of  claim 20  further comprising comparing the measured levels of expression or protein with levels from controls obtained from individuals with confirmed infection. 
     
     
         27 . The method of  claim 20  wherein the clinical samples and controls are obtained from individuals with confirmed inflammation due to gout or autoimmune disease. 
     
     
         28 . The method of  claim 20  wherein the expression is compared by comparing protein expressed from the genes. 
     
     
         29 . The method of  claim 20  wherein the genes are selected from the group consisting of P13, TNFAIP6, GPR43, GBP1, CCL4, CCL3, HM74, MAFF, PLAU, GCH1, SOD2, SLP1, HIG2, IL1RN, FABP5, LIPA, CD36, CD9, GPNMB, FCER1A, FN1, LOC115207, Z39 IG, MAFB, LGMN, CD36, FN1, C6orf62, and MS4A4A. 
     
     
         30 . The method of  claim 20  wherein the expression or protein levels are three fold different. 
     
     
         31 . The method of  claim 20  wherein the expression or protein levels are five fold different. 
     
     
         32 . The method of  claim 20  wherein the expression or protein levels are ten fold different. 
     
     
         33 . The method of  claim 20  wherein the proteins are selected from the group consisting of skin-derived antileukoproteinase (SKALP) (PI3), interleukin-1beta (IL1B), interleukin-8 (IL8), Interleukin-1 receptor-associated kinase 3 (IRAK3), CC chemokine ligand 3 (CCL3), CC chemokine ligand 4 (CCL4), superoxide dismutase 2 (SOD2), Nuclear Factor of Kappa light polypeptide gene enhancer in B-cells Inhibitor, Alpha (NFKBIA), Nijmegen breakage syndrome 1 (NBS 1), tumor necrosis factor alpha-induced protein 6 (TNFAIP6), and plasminogen activator, urokinase (PLAU).